Jakafi in Chronic GVHD
Immune Cell Proliferation and Cytokine Signaling
JAK-STAT signaling pathways help regulate the development, proliferation, and activation of immune cell types important for GVHD1-4
- Signaling by proinflammatory cytokines
- Trafficking of T cells and innate immune cells to tissues
- Proliferation and activation of T cells
- Suppression of regulatory T cells (Tregs)


GVHD, graft-versus-host disease; JAK, Janus-associated kinase; STAT, signal transducer and activator of transcription.
References
- Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation.
- Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, von Bubnoff N. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018;10(5):391-402.
- Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-2068.
- Schroeder MA, Choi J, Staser K, DiPersio JF. The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia. Biol Blood Marrow Transplant. 2018;24(6):1125-1134.